Bromide

Bromide

SCHEMBL1731787

Br.CCc1ccc2c(n1)C(=N)N(CC(=O)c1ccc(O)c(C(C)(C)C)c1)C2

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 12/20 0.40
HSP90AB1 P08238 10/20 0.40
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
F2R P25116 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1730897 0.90 F2R (0.42) KDM4EMAPTRAB9ANPC1F2R
SCHEMBL6545085 0.89 KDM4E (0.35) HSP90AA1HSP90AB1KDM4EMAPTRAB9A
SCHEMBL14449085 0.89 F2R (0.43) KDM4EMAPTRAB9AF2RSMN1; SMN2
Bromide SCHEMBL1729851 0.88 KDM4E (0.35) KDM4EMAPTRAB9ANPC1F2R
Bromide SCHEMBL5486668 0.86 F2R (0.44) KDM4EMAPTRAB9ANPC1F2R
Bromide SCHEMBL1731726 0.86 KDM4E (0.34) KDM4EMAPTRAB9ANPC1F2R
Bromide SCHEMBL5488725 0.86 F2R (0.39) KDM4EMAPTRAB9ANPC1F2R
Bromide SCHEMBL1731367 0.85 F2R (0.37) KDM4EMAPTRAB9ANPC1F2R
SCHEMBL1731383 0.85 F2R (0.43) KDM4EMAPTRAB9ANPC1F2R
Bromide SCHEMBL1730139 0.85 NPC1 (0.33) KDM4EMAPTRAB9ANPC1F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1391451-A1 2-IMINOPYRROLIDINE DERIVATES Eisai Co., Ltd. (JP) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 HSP90AA1 1439/4885HSP90AB1 1613/4885KDM4E 3161/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 HSP90AA1 1438/4885HSP90AB1 1605/4885KDM4E 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.